These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29947424)

  • 21. The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma.
    Prall F; Hühns M
    Histopathology; 2017 Sep; 71(3):366-374. PubMed ID: 28383777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Liu K; Zhao K; Wang L; Sun E
    Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
    Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X
    Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
    J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
    Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.
    Tsai YS; Jou YC; Tung CL; Lin CT; Shen CH; Chen SY; Tsai HT; Lai CL; Wu CL; Tzai TS
    Virchows Arch; 2014 Jun; 464(6):717-24. PubMed ID: 24733561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.
    Stakhovskyi O; Kobyliak N; Voylenko O; Stakhovskyi E; Ponomarchuk R; Sulaieva O
    Cells; 2022 May; 11(11):. PubMed ID: 35681497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.
    Papadopoulou K; Koliou GA; Tsimiliotis D; Kotoula V; Foukas P; Goussia A; Tsiatas M; Visvikis A; Chatzopoulos K; Nifora M; Charchanti A; Koumarianou A; Christodoulou C; Pectasides D; Psyrri A; Fostira F; Fountzilas G; Samantas E
    Urol Oncol; 2022 Dec; 40(12):538.e15-538.e24. PubMed ID: 36041976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.
    De Logu F; Galli F; Nassini R; Ugolini F; Simi S; Cossa M; Miracco C; Gianatti A; De Giorgi V; Rulli E; Cossu A; Massi D; Mandalà M
    Cells; 2021 Feb; 10(2):. PubMed ID: 33671367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.